Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot multiple dose study of MRx-4DP0004 in hospitalised patients with symptoms of COVID-19
2020-001597-30Phase 2Unknown
- Sponsor
- 4D Pharma plc
- Start
- Apr 2020
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of MRx-4DP0004 in coronavirus disease 2019 (COVID-19), sponsored by 4D Pharma plc. Primary endpoint: Change in mean clinical status score. Status: unknown.
02
Drugs
MRx-4DP0004
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001597-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001597-30.